Grant of Interim Extension of the Term of U.S. Patent No. 5,454,779; ResQPump®/ResQPOD® ITD, 61579 [2012-24856]

Download as PDF Federal Register / Vol. 77, No. 196 / Wednesday, October 10, 2012 / Notices DEPARTMENT OF COMMERCE United States Patent and Trademark Office [Docket No. PTO–P–2012–0039] Grant of Interim Extension of the Term of U.S. Patent No. 5,454,779; ResQPump®/ResQPOD® ITD United States Patent and Trademark Office, Commerce. ACTION: Notice of Interim Patent Term Extension. AGENCY: The United States Patent and Trademark Office has issued an order granting interim extension under 35 U.S.C. 156(d)(5) for a one-year interim extension of the term of U.S. Patent No. 5,454,779. FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571) 272– 7755; by mail marked to her attention and addressed to the Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, Alexandria, VA 22313– 1450; by fax marked to her attention at (571) 273–7755; or by email to Mary. Till@uspto.gov. SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to one year if the regulatory review is anticipated to extend beyond the expiration date of the patent. On September 6, 2012, the Regents of the University of California timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of U.S. Patent No. 5,454,779. The patent claims the medical device, ResQPump® in connection with the ResQPOD® ITD. The application indicates that a Premarket Approval Application, PMA No. P110024, for the medical device has been filed, and is currently undergoing regulatory review before the Food and Drug Administration for permission to market or use the product commercially. Review of the application indicates that, except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for one year as required by 35 U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory review period will continue beyond the original expiration date of the patent, October 3, rmajette on DSK2TPTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 15:15 Oct 09, 2012 Jkt 229001 2012, interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate. An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 5,454,779 is granted for a period of one year from the original expiration date of the patent. Dated: September 27, 2012. Andrew Hirshfeld, Deputy Commissioner for Patent Examination Policy, United States Patent and Trademark Office. [FR Doc. 2012–24856 Filed 10–9–12; 8:45 am] BILLING CODE 3510–16–P BUREAU OF CONSUMER FINANCIAL PROTECTION Agency Information Collection Activities: Submission for OMB Review; Comment Request Bureau of Consumer Financial Protection. ACTION: Notice and request for comment. AGENCY: The Bureau of Consumer Financial Protection (Bureau), as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed information collections, as required by the Paperwork Reduction Act of 1995. The Bureau is soliciting comments concerning its proposed information collections titled, ‘‘Generic Clearance for Collection of Information on Compliance Costs and Other Effects of Regulations.’’ A proposed collection has been submitted to the Office of Management and Budget (OMB) for review and approval. A copy of the submission, including copies of a proposed collection and supporting documentation, may be obtained by contacting the agency contact listed below. SUMMARY: Written comments are encouraged and must be received on or before November 9, 2012 to be assured of consideration. ADDRESSES: You may submit comments, identified by agency name and Generic Clearance for Collection of Information on Compliance Costs and Other Effects of Regulations, to: • Agency: Consumer Financial Protection Bureau (Attention: PRA Office), 1700 G Street NW., Washington, DC 20552; (202) 435–9011; and CFPB_ Public_PRA@cfpb.gov. • OMB: Shagufta Ahmed, Office of Management and Budget, New DATES: PO 00000 Frm 00011 Fmt 4703 Sfmt 4703 61579 Executive Office Building, Room 10235, Washington, DC 20503; (202) 395–7873. FOR FURTHER INFORMATION CONTACT: Requests for additional information should be directed to Consumer Financial Protection Bureau (Attention: PRA Office), 1700 G Street NW., Washington, DC 20552, (202) 435–9011, or through the internet at CFPB_Public_ PRA@cfpb.gov. SUPPLEMENTARY INFORMATION: Title: Generic Clearance for Collection of Information on Compliance Costs and Other Effects of Regulations. OMB Control Number: 3170–XXXX. Type of Review: New generic collection. Abstract: Congress created the Bureau in July 2010 through the Dodd-Frank Wall Street Reform and Consumer Protection Act, Public Law 111–203, Title X (the Dodd-Frank Act), and the Bureau assumed certain rulemaking authorities in July 2011. The DoddFrank Act accords the Bureau responsibility for implementing, interpreting, and assuring compliance with various Federal consumer financial protection products and services. As outlined in the Dodd-Frank Act, among the Bureau’s objectives is to identify regulations that are ‘‘outdated, unnecessary, or unduly burdensome’’ in order to reduce unwarranted regulatory burdens. In order to help support this objective, the Bureau must fully understand the implications of its regulations. Therefore, the Bureau seeks to collect qualitative information on compliance costs and other impacts of existing consumer financial regulations and any new potential rules the Bureau may propose. The collections seek qualitative information on the impact of regulations on providers of consumer financial products and services (Providers). The Bureau seeks to better understand the compliance activities, burdens, and other economic costs and benefits associated with its potential rules and existing regulations. Additional input from Providers would give the Bureau a more nuanced understanding of costs, which it can use to provide solutions for reducing undue regulatory burden on Providers. To that end, the Bureau anticipates seeking to use the information from these collections to: • Inform the Bureau’s various rulemaking initiatives announced in the Bureau’s regulatory agenda, most of which concern the mortgage industry; 1 1 Consumer Financial Protection Bureau, ‘‘Fall 2011 Statement of Regulatory Priorities,’’ (available at http://www.consumerfinance.gov/regulations/ fall-2011-statement-of-regulatory-priorities/); E:\FR\FM\10OCN1.SGM Continued 10OCN1

Agencies

[Federal Register Volume 77, Number 196 (Wednesday, October 10, 2012)]
[Notices]
[Page 61579]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-24856]



[[Page 61579]]

-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

[Docket No. PTO-P-2012-0039]


Grant of Interim Extension of the Term of U.S. Patent No. 
5,454,779; ResQPump[supreg]/ResQPOD[supreg] ITD

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Notice of Interim Patent Term Extension.

-----------------------------------------------------------------------

SUMMARY: The United States Patent and Trademark Office has issued an 
order granting interim extension under 35 U.S.C. 156(d)(5) for a one-
year interim extension of the term of U.S. Patent No. 5,454,779.

FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571) 
272-7755; by mail marked to her attention and addressed to the 
Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, 
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755; or by email to Mary.Till@uspto.gov.

SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, 
generally provides that the term of a patent may be extended for a 
period of up to five years if the patent claims a product, or a method 
of making or using a product, that has been subject to certain defined 
regulatory review, and that the patent may be extended for interim 
periods of up to one year if the regulatory review is anticipated to 
extend beyond the expiration date of the patent.
    On September 6, 2012, the Regents of the University of California 
timely filed an application under 35 U.S.C. 156(d)(5) for an interim 
extension of the term of U.S. Patent No. 5,454,779. The patent claims 
the medical device, ResQPump[supreg] in connection with the 
ResQPOD[supreg] ITD. The application indicates that a Premarket 
Approval Application, PMA No. P110024, for the medical device has been 
filed, and is currently undergoing regulatory review before the Food 
and Drug Administration for permission to market or use the product 
commercially.
    Review of the application indicates that, except for permission to 
market or use the product commercially, the subject patent would be 
eligible for an extension of the patent term under 35 U.S.C. 156, and 
that the patent should be extended for one year as required by 35 
U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory review 
period will continue beyond the original expiration date of the patent, 
October 3, 2012, interim extension of the patent term under 35 U.S.C. 
156(d)(5) is appropriate.
    An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. 
Patent No. 5,454,779 is granted for a period of one year from the 
original expiration date of the patent.

    Dated: September 27, 2012.
Andrew Hirshfeld,
Deputy Commissioner for Patent Examination Policy, United States Patent 
and Trademark Office.
[FR Doc. 2012-24856 Filed 10-9-12; 8:45 am]
BILLING CODE 3510-16-P